Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study
© 2024 British Society for Haematology and John Wiley & Sons Ltd..
Due in part to racial disparities and underrepresentation in clinical studies, optimal therapies for Black patients with multiple myeloma remain undefined. This final analysis of GRIFFIN by race showed that the addition of daratumumab (D) to lenalidomide/bortezomib/dexamethasone (RVd) provides clinical benefit among both Black and White transplant-eligible newly diagnosed patients compared with RVd alone. However, Black patients were more likely to discontinue ≥1 drug due to treatment-emergent adverse events. In summary, these findings suggest a benefit of D-RVd front-line therapy among Black and White patients and underscore the importance of equitable treatment access for all patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
British journal of haematology - (2024) vom: 19. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nooka, Ajay K [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibody therapy |
|---|
| Anmerkungen: |
Date Revised 20.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1111/bjh.19386 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369941535 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369941535 | ||
| 003 | DE-627 | ||
| 005 | 20240320235409.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240320s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bjh.19386 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1337.xml |
| 035 | |a (DE-627)NLM369941535 | ||
| 035 | |a (NLM)38504552 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nooka, Ajay K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 20.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024 British Society for Haematology and John Wiley & Sons Ltd. | ||
| 520 | |a Due in part to racial disparities and underrepresentation in clinical studies, optimal therapies for Black patients with multiple myeloma remain undefined. This final analysis of GRIFFIN by race showed that the addition of daratumumab (D) to lenalidomide/bortezomib/dexamethasone (RVd) provides clinical benefit among both Black and White transplant-eligible newly diagnosed patients compared with RVd alone. However, Black patients were more likely to discontinue ≥1 drug due to treatment-emergent adverse events. In summary, these findings suggest a benefit of D-RVd front-line therapy among Black and White patients and underscore the importance of equitable treatment access for all patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a antibody therapy | |
| 650 | 4 | |a clinical trials | |
| 650 | 4 | |a complete remission | |
| 650 | 4 | |a haematological malignancy | |
| 650 | 4 | |a minimal residual disease | |
| 650 | 4 | |a multiple myeloma | |
| 700 | 1 | |a Kaufman, Jonathan L |e verfasserin |4 aut | |
| 700 | 1 | |a Rodriguez, Cesar |e verfasserin |4 aut | |
| 700 | 1 | |a Jakubowiak, Andrzej |e verfasserin |4 aut | |
| 700 | 1 | |a Efebera, Yvonne |e verfasserin |4 aut | |
| 700 | 1 | |a Reeves, Brandi |e verfasserin |4 aut | |
| 700 | 1 | |a Wildes, Tanya M |e verfasserin |4 aut | |
| 700 | 1 | |a Holstein, Sarah A |e verfasserin |4 aut | |
| 700 | 1 | |a Anderson, Larry D |c Jr |e verfasserin |4 aut | |
| 700 | 1 | |a Badros, Ashraf |e verfasserin |4 aut | |
| 700 | 1 | |a Shune, Leyla |e verfasserin |4 aut | |
| 700 | 1 | |a Chari, Ajai |e verfasserin |4 aut | |
| 700 | 1 | |a Pei, Huiling |e verfasserin |4 aut | |
| 700 | 1 | |a Cortoos, Annelore |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Sharmila |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Thomas S |e verfasserin |4 aut | |
| 700 | 1 | |a Voorhees, Peter M |e verfasserin |4 aut | |
| 700 | 1 | |a Usmani, Saad Z |e verfasserin |4 aut | |
| 700 | 1 | |a Richardson, Paul G |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of haematology |d 1955 |g (2024) vom: 19. März |w (DE-627)NLM000000396 |x 1365-2141 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:19 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bjh.19386 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 19 |c 03 | ||